ClinicalTrials.gg
CompletedNCT03335007Updated Nov 7, 2017

Pretreatment Aceclofenac Effect on Pain and Analgesic Intake After Endodontic Treatment

A Phase 2/3 interventional study of Aceclofenac and Placebo in Symptomatic Irreversible Pulpitis, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-07.

Sponsored by Cairo University · Phase 2/3, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled May 2015, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 103 studies in Pain by Cairo University — 31 open to participants now, 34 under way, 2 of them phase 3. Pain · Cairo University.

Enrollment
39th of 100
70 · median 60
Started
2015
with 10 others
Phase 2/3
3 of 103
1 open now
Registered
25th of 103
by date

Among the 103 studies in Pain by Cairo University, this one is the 39th largest by enrollment of the 100 interventional ones that give a count, is one of 11 that started in 2015, is one of 3 in phase 2/3, and was the 25th registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

31 of the 103 studies in Pain by Cairo University are open now, in 1 country. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Pain by Cairo University, or all of them as a file.
02

Study summary

The aim of this prospective, randomized, double-blind, clinical trial is to evaluate the effect of a preoperative, single, oral dose of aceclofenac (100 mg) on postendodontic pain at 6, 24 and 48 hours, postoperative pain at injection area at 6, 24 and 48 hours and analgesic intake after single-visit root canal treatment.

Read the detailed description
  • Patients will be clinically and radiographically examined and their eligibility will be assessed and preoperative pain will be measured using Heft-Parker VAS. Eligible patients will be treated in one visit.
  • Patients will be randomly assigned to one of 2 groups: experimental group (taking a 100 mg of Aceclofenac) and the control group (taking a placebo tablet). Each tablet will be taken one hour before the initiation of single-visit endodontic therapy. Each participant will receive a standard inferior alveolar nerve block injection of 1.8 ml of 2% mepivacaine with 1:100,000 epinephrine. After endodontic treatment, patients will be given postoperative instructions and informed, in case of pain, to receive ibuprofen 200 mg as rescue medication.
  • Postendodontic pain intensity and incidence at the different pain categories (No, mild, moderate, severe) will be assessed 6, 24, and 48 hours postoperatively using Heft-Parker visual analogue scale (HP-VAS). Postoperative pain at injection area will be assessed at 6,24 and 48 hours using HP-VAS. Analgesic intake throughout the 48 hours will be recorded.
03

Conditions studied

  • Symptomatic Irreversible Pulpitis

Browse trials for

Keywords

  • Aceclofenac
  • pain
  • irreversible pulpitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients in good health ( Class I or Class II).
  • Patients having symptomatic irreversible pulpitis in one of their mandibular molars
  • Age is 18 years or older.
  • Patients who can understand Heft- Parker Visual Analogue Scales.
  • Patients able to sign .

Exclusion criteria

Exclusion Criteria:

  • Patients allergic to aceclofenac or Mepivacaine.
  • Pregnant or nursing women.
  • Patients having active pain in more than one molar in the same quadrant.
  • Administration of analgesics within 12 h before the administration of the study drug.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Aceclofenac

    Aceclofenac 100 mg tablet

    Drug: Aceclofenac

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • Aceclofenac 100 mg tablet given one hour before starting the root canal treatment

    Also known as: Bristaflam

  • OtherPlacebo

    Placebo tablet given one hour before starting the root canal treatment

06

What researchers measure

Primary outcomes

  1. Postendodontic pain rate change

    Postendodontic pain will be measured using Heft-Parker visual analogue scale. No or mild pain response will be considered success.

    Time frame: At 6, 24 and 48 hours after root canal treatment.

Secondary outcomes

  1. Postoperative pain at injection area

    Postoperative pain at injection area will be measured with Heft-Parker visual analogue scale. No or mild pain response will be considered success.

    Time frame: At 6, 24 and 48 hours after root canal treatment.

  2. Analgesic intake

    Incidence of analgesic intake

    Time frame: Within 48 hours after single root canal treatment.

07

Study locations

1 site
  • Cairo University
    Cairo, 11553, Egypt
08

References and documents

Publications

  • Praveen R, Thakur S, Kirthiga M. Comparative Evaluation of Premedication with Ketorolac and Prednisolone on Postendodontic Pain: A Double-blind Randomized Controlled Trial. J Endod. 2017 May;43(5):667-673. doi: 10.1016/j.joen.2016.12.012. Epub 2017 Mar 17. PubMed 28320541 ↗
  • Attar S, Bowles WR, Baisden MK, Hodges JS, McClanahan SB. Evaluation of pretreatment analgesia and endodontic treatment for postoperative endodontic pain. J Endod. 2008 Jun;34(6):652-5. doi: 10.1016/j.joen.2008.02.017. Epub 2008 Apr 2. PubMed 18498882 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Jul 2017, 26 months.

Of 35 non-industry phase 2/3 interventional studies under Pain, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 26 months is above that.

Counting every sponsor, half of 41 studies reached it within 20 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2017
First posted
Nov 7, 2017
StartActual
May 2015
Primary completionActual
Jul 2017
CompletionActual
Jul 2017
Last update
Nov 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03335007
Lead sponsor
Cairo University
Responsible party
Nermeen AwadAllah Abbas Ibrahim (Principal Investigator, Cairo University, Cairo University) — Principal investigator
First posted
Nov 7, 2017
Start date
May 2015
Primary completion
Jul 2017
Completion
Jul 2017
Last update
Nov 7, 2017

Study contacts

Nermeen A Abbas, Postgraduate
principal investigator · Cairo University
Suzan AW Amin, PhD
study director · Cairo University
Shaimaa Gawdat, PhD
study chair · Cairo University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aceclofenac

Start the discussion